The study population appropriately demonstrated the expected spectrum of pathological and cytogenetic risk features in neuroblastoma: 9/13 (70%) had stage 4 disease and 3/13 (23%) had MYCN amplification (Supplementary Table S1). Here, MYCN is linked to neuroblastoma.